Trial
NCT03086395
Single Agent Obinutuzumab in Relapsed/Refractory Post-Transplant Lymphoproliferative Disorder (PTLD)
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Case Comprehensive Cancer Center
Collaborators
Genentech, Inc.
Condition
Post-transplant Lymphoproliferative Disorder
Intervention
Obinutuzumab
Why stopped
Funding Unavailable
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-03-22